MetaCap

NeoGenomics (NEO) vs UL Solutions (ULS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeoGenomics (NEO) has outperformed UL Solutions (ULS) over the past year, gaining 29.1% versus a loss of 15.2%. UL Solutions is the larger company by market cap ($14.67 billion vs $1.92 billion), about 7.6 times the size, while NeoGenomics is growing revenue faster (+10.1% vs +6.4%). On valuation, UL Solutions trades at a lower forward P/E (27.5x vs 47.1x for NeoGenomics).

UL Solutions pays a dividend yielding 0.78%, while NeoGenomics does not currently pay one. UL Solutions converts more of its revenue into profit, with a net margin of 10.6% versus -14.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NEO+29.09%ULS-15.24%
+79%+18%-43%
Nov 21, 20251 yearNov 20, 2026
NEO+5.18%ULS+107.90%
+207%+65%-76%
Apr 8, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NEO versus ULS key metrics
MetricNEOULS
Share price$14.82$72.64
Market cap$1.92B$14.67B
1-day change-1.79%-2.99%
YTD return+26.02%-7.89%
1-year return+29.09%-15.24%
5-year return-59.56%—
P/E ratio (TTM)—28.83
Forward P/E47.1127.49
EPS (TTM)$-0.24$2.52
Dividend yield0.00%0.78%
Annual dividend$0.00$0.565
Revenue (latest FY)$727.33M$3.05B
Revenue growth (YoY)+10.11%+6.38%
Net income (latest FY)$-108.03M$325.00M
Gross margin43.21%49.46%
Operating margin-15.93%17.10%
Net margin-14.85%10.65%
52-week high$20.15$107.54
52-week low$7.07$63.17
Distance from 52-week high-26.45%-32.45%
Analyst consensusnonebuy
Avg. price target upside+57.89%+32.78%
Average volume1.96M873.95K
Shares outstanding129.39M78.15M
Employees2,50014,587
SectorHealth CareHealth Care
IndustryPrecision InstrumentsPrecision Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UL Solutions is about 7.6 times larger than NeoGenomics by market value ($14.67B vs $1.92B).
  • NEO has outperformed ULS by 44.3 percentage points over the past year.
  • UL Solutions is more profitable, keeping 10.6 cents of every revenue dollar as net income versus -14.9 cents for NeoGenomics.

About NeoGenomics

NEO stock →

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.

Health Care · Precision Instruments · 2,500 employees

About UL Solutions

ULS stock →

UL Solutions Inc., together with its subsidiaries, provides testing, inspection and certification services and related software and advisory services worldwide. It operates through three segments: Industrial, Consumer, and Software and Advisory.

Health Care · Precision Instruments · 14,587 employees

NEO vs ULS FAQ

Which is bigger, NeoGenomics or UL Solutions?

UL Solutions (ULS) is larger, with a market capitalization of $14.67B compared with $1.92B for NeoGenomics (NEO).

Which stock has performed better over the past year, NEO or ULS?

NEO returned +29.09% over the past 12 months, compared with -15.24% for ULS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, NeoGenomics or UL Solutions?

UL Solutions pays a dividend yielding 0.78%, while NeoGenomics does not currently pay a regular dividend.

Are NeoGenomics and UL Solutions in the same industry?

Yes. Both are classified in the Precision Instruments industry within the Health Care sector.

More comparisons